IGC Pharma (IGC) Receivables - Other (2011 - 2026)

IGC Pharma (IGC) has reported Receivables - Other for 16 consecutive years, with $657000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $657000.0 in Q1 2026; TTM through Mar 2026 was $657000.0, a 812.5% increase from a year earlier, with the FY2026 full-year figure at $657000.0, down 3.38% from the prior year.
• Receivables - Other was $657000.0 for Q1 2026 at IGC Pharma, down from $667000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $951000.0 in Q2 2023 and troughed at -$311000.0 in Q1 2024.
• A 5-year average of $593500.0 and a median of $679500.0 in 2024 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other soared 168.64% in 2023 and tumbled 627.12% in 2024, its largest moves.
• Over 5 years, Receivables - Other stood at $751000.0 in 2022, then rose by 25.97% to $946000.0 in 2023, then retreated by 28.22% to $679000.0 in 2024, then declined by 1.77% to $667000.0 in 2025, then retreated by 1.5% to $657000.0 in 2026.
• The last three Receivables - Other figures came in at $657000.0 (Q1 2026), $667000.0 (Q4 2025), and $670000.0 (Q3 2025), per Business Quant data.